Free Trial
NASDAQ:ENGN

enGene (ENGN) Stock Price, News & Analysis

enGene logo
$3.62 -0.04 (-1.01%)
As of 12:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About enGene Stock (NASDAQ:ENGN)

Key Stats

Today's Range
$3.49
$3.68
50-Day Range
$2.88
$4.29
52-Week Range
$2.65
$11.00
Volume
9,881 shs
Average Volume
128,920 shs
Market Capitalization
$184.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.29
Consensus Rating
Buy

Company Overview

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

enGene Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

ENGN MarketRank™: 

enGene scored higher than 56% of companies evaluated by MarketBeat, and ranked 497th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    enGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    enGene has only been the subject of 1 research reports in the past 90 days.

  • Read more about enGene's stock forecast and price target.
  • Earnings Growth

    Earnings for enGene are expected to decrease in the coming year, from ($1.56) to ($1.84) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of enGene is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of enGene is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    enGene has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.23% of the float of enGene has been sold short.
  • Short Interest Ratio / Days to Cover

    enGene has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in enGene has recently increased by 29.55%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    enGene does not currently pay a dividend.

  • Dividend Growth

    enGene does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.23% of the float of enGene has been sold short.
  • Short Interest Ratio / Days to Cover

    enGene has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in enGene has recently increased by 29.55%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    enGene has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for enGene this week, compared to 12 articles on an average week.
  • MarketBeat Follows

    Only 3 people have added enGene to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, enGene insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.40% of the stock of enGene is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about enGene's insider trading history.
Receive ENGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for enGene and its competitors with MarketBeat's FREE daily newsletter.

ENGN Stock News Headlines

The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Brokerages Set enGene Holdings Inc. (NASDAQ:ENGN) PT at $23.29
See More Headlines

ENGN Stock Analysis - Frequently Asked Questions

enGene's stock was trading at $6.65 at the start of the year. Since then, ENGN stock has decreased by 45.8% and is now trading at $3.6050.
View the best growth stocks for 2025 here
.

enGene Holdings Inc. (NASDAQ:ENGN) issued its quarterly earnings data on Tuesday, June, 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.03.

Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that enGene investors own include PayPal (PYPL), United Microelectronics (UMC), XPeng (XPEV), Adverum Biotechnologies (ADVM), AngioDynamics (ANGO), APi Group (APG) and Avino Silver & Gold Mines (ASM).

Company Calendar

Last Earnings
6/10/2025
Today
6/30/2025
Fiscal Year End
10/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENGN
Previous Symbol
NASDAQ:ENGN
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.29
High Stock Price Target
$34.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+536.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$55.14 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$5.35 per share
Price / Book
0.68

Miscellaneous

Free Float
45,790,000
Market Cap
$187.03 million
Optionable
N/A
Beta
-0.40
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:ENGN) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners